Hollow sponge spicule, and preparation method therefor and use thereof

By treating the sponge bone needle with alkaline solution, the internal closed channel is opened to form a hollow channel, which solves the problem of insufficient permeability of natural sponge bone against biological macromolecules, and significantly improves the percutaneous delivery efficiency of drugs and cosmetics.

WO2024235113A1PCT designated stage expired Publication Date: 2024-11-21XIAMEN UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092258
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Due to the closed internal channels of natural sponge bone needles, it is difficult to effectively promote the transdermal delivery of biological macromolecules, and their osmotic effect on macromolecules is limited.

Method used

By putting the sponge bone needle into an alkaline solution for soaking and shocking treatment, the silicone protein tip structure dissolves, forming a hollow channel, thereby improving the mechanical strength and permeability efficiency of the bone needle.

Benefits of technology

The preparation of hollow sponge bone needles has been realized, which significantly improves the percutaneous absorption efficiency and utilization rate of biological macromolecules such as drugs and cosmetics, and is suitable for the delivery of biological macromolecules with large molecular weight.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092258_21112024_PF_FP_ABST
    Figure CN2024092258_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A hollow sponge spicule, and a preparation method therefor and a use thereof. Specifically disclosed are a preparation method for a hollow sponge spicule using a sponge Haliclona sp. spicule and the like as basic raw materials, and characterization data after treatment with the preparation method. According to the preparation method, an alkaline solution prepared from sodium hydroxide is used as a treating agent, and a sponge spicule is soaked and shaken, so as to achieve the purpose of reacting the alkaline solution with a silicon substance contained in the spicule, thereby generating a hollow channel in the spicule. Thus, the efficiency of transdermal drug delivery is improved, the drug utilization rate is improved, and more efficient, stable and safe transdermal absorption of a series of biomacromolecules such as drugs and cosmetic active components is promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Hollow sponge spicules and their preparation method and application

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority based on the Chinese patent application filed with the State Intellectual Property Office of China on May 12, 2023, with application number: 2023105345411, and the name of the invention: "Hollow sponge bone needle and its preparation method and application". The content of the Chinese patent application is hereby introduced into the text of this application. Technical Field

[0003] The present invention relates to the field of biomaterials, in particular to a biomaterial and material improvement thereof under artificial preparation processing conditions, and using the improved material in transdermal delivery. Background Art

[0004] The skin is the largest organ in the human body and also the most direct route for drug administration. Compared to other routes of administration (such as oral administration and injection), transdermal drug delivery offers many unique advantages, including avoiding the first-pass effect on the liver, gastrointestinal damage, and the infection and pain caused by injections. Furthermore, it can act directly on localized skin lesions, allowing for sustained-release or controlled-release drug delivery, with minimal adverse reactions and the ability to terminate drug administration at any time, greatly improving patient convenience and compliance.

[0005] However, the essence of the skin is a biomembrane barrier, especially its outermost layer, the stratum corneum, which protects the body from the invasion of various harmful substances and exogenous pathogens (such as bacteria, fungi, parasites, viruses, heavy metals and various chemical toxins). Generally, only a very small number of small molecules (molecular weight <500Da) can effectively pass through the skin's stratum corneum barrier, while the vast majority of drug molecules or bioactive ingredients, especially the increasingly popular biomacromolecule drugs and active substances, including polysaccharides, peptides, proteins, nucleic acids, siRNA, etc., are difficult to penetrate and absorb through the skin. Therefore, how to overcome the skin barrier and safely and effectively deliver various biomacromolecule drugs or active substances with different physical and chemical properties through the skin to the lesion site is a very challenging task, and it is also a research difficulty and hotspot in the field of skin drug delivery.

[0006] Currently, methods for promoting transdermal absorption of drugs or active substances can be broadly categorized into chemical and physical methods. Chemical methods primarily include chemical penetration enhancers (e.g., DMSO, azones, and pyrrolidones), polypeptide penetration enhancers (e.g., SPACE), and nanocarrier systems (e.g., liposomes, microemulsions, transdermal gels, and transfersomes). While chemical methods offer advantages such as low cost, rapid onset, and ease of use, their effectiveness is relatively limited. Furthermore, some penetration enhancers are inherently toxic, and long-term use can disrupt the skin's barrier structure, causing skin irritation and allergies, and even systemic toxic reactions, severely limiting their application. Physical methods primarily include sonophoresis, iontophoresis, electroporation, thermal cauterization, laser microdrilling, and microneedling. While some of these methods are highly effective, they require high instrumentation, have high design and production costs, and are difficult to port. Furthermore, their invasive delivery methods often result in a range of issues, including stinging, skin irritation, and burning. Furthermore, they are only suitable for small skin areas, significantly limiting their application.

[0007] Microneedle technology is a new physical penetration enhancement method that has emerged in recent years. It can create a large number of micron-sized channels on the skin's surface in a minimally invasive manner. With diameters ranging from 50 to 200 μm and lengths ranging from several hundred microns to several millimeters, microneedles can penetrate the stratum corneum, reaching the epidermis and even the dermis, while remaining remarkably inaccessible to pain-sensing nerves in the dermis. Furthermore, microneedling can create numerous microscopic water pores in the stratum corneum, facilitating the entry of a range of drugs, including polysaccharides, peptides, proteins, hormones, vaccines, and other bioactive ingredients, as well as cosmetic active ingredients and nanocarrier systems, into the body. These drugs can be used to treat and prevent skin problems and various diseases, with promising applications and few reported side effects.

[0008] However, due to the elasticity of the skin itself, the microchannels formed by the microneedles on the skin surface usually close automatically within 10 to 20 minutes, resulting in a very limited effective penetration time for drugs, cosmetic active ingredients or nanocarrier particles. Currently, microneedle technology is mainly used to deliver drugs in the form of microneedle patches. Long-term use may cause skin allergies. At the same time, the delivery area of ​​the microneedle patch is fixed and relatively limited. Although expanding the delivery area can increase the degree of drug penetration, it will also increase irritation to the skin and reduce patient compliance with medication. Therefore, it is generally only suitable for the delivery of small-dose and highly active drugs, such as insulin or vaccine products. In addition, the sharpness of the microneedle end and the density of the microneedle arrangement depend on its production and etching process, and the requirements for its preparation material, preparation process and industrialization are relatively high. In addition, the microneedles are usually arranged in an array, which makes it difficult to work on non-flat areas such as the nose.

[0009] Sponge spicules are fibrous, silica or calcium structures that serve as the skeleton of sponges. They exhibit a variety of structural morphologies, including uniaxial, biaxial, triaxial, and multiaxial. Studies have shown that sponge spicules possess excellent optical and mechanical properties. Current research on sponge spicules focuses on their optical properties, nanostructures, and biomimetics. However, relatively little research and development has been conducted on sponge spicules, which naturally possess high mechanical strength and sharp tips and may have similar effects to microneedles. We have innovatively investigated the potential of sponge spicules as microneedle-like physical permeation enhancers. Compared to microneedles, these spicules offer several advantages, including flexibility in dosage, application method, and application area; prolonged retention in the stratum corneum, and the formation of numerous persistent nanoscale channels, thereby enhancing the transdermal absorption of biomacromolecules or active ingredients. However, this approach has limitations and is best suited for relatively small and stable drugs or cosmetic active ingredients. Its permeation-enhancing effect on biomacromolecules with large molecular weights or poor stability (>5 kDa) remains limited. Therefore, the purpose of the present invention is to appropriately modify the existing sponge spicules to improve their penetration-promoting effect on biomacromolecules.

[0010] Summary of the Invention

[0011] The purpose of the present invention is to overcome the above-mentioned shortcomings of natural sponge spicules, provide hollow sponge spicules and their preparation method, and use of macromolecular active ingredients (>5KDa) to promote penetration.

[0012] Natural sponge spicules (such as bee sponge spicules or similar spicules) are formed using silica protein as a template. Therefore, after the natural sponge spicule is formed, a channel is formed inside around the silica protein, but 1) there is silica protein inside this channel, and 2) the tip of the spicule is closed, so the natural sponge spicule only has a closed internal channel, but does not have a through, open hollow channel. The present invention uses an alkaline solution to soak a sponge spicule containing a closed channel (occupied by silica protein when the spicule is formed) and artificially shakes it. Through the reaction of the silicon substance on the surface of the sponge spicule with the alkaline solution, the tip structure of the sponge spicule is dissolved, the internal closed channel is connected to the outside, and the internal silica protein is also released, so that it produces the effect of a hollow channel, while retaining good mechanical strength and spicule integrity, realizing the construction of the sponge spicule hollow channel (the average diameter of the hollow channel is 1.2 microns, which is a micron-level channel), thereby improving the efficiency of transdermal delivery, greatly promoting more efficient, stable and safe transdermal absorption of a series of biomacromolecules such as drugs and cosmetic active ingredients, and improving utilization rate.

[0013] One of the technical solutions adopted by the present invention to solve the technical problem is:

[0014] A hollow sponge spicule has at least one hollow channel inside.

[0015] Preferably, the channel has at least two openings on the surface of the hollow sponge spicule.

[0016] Preferably, each of the channels has at least one opening at each end of the hollow sponge spicule.

[0017] Preferably, the hollow sponge spicule is in the shape of a slender rod, and the channels are arranged along the length direction of the hollow sponge spicule.

[0018] More preferably, the hollow sponge bone needle is in the shape of a slender rod, and has a hollow channel inside. The hollow channel has at least two openings on the surface of the hollow sponge bone needle, and the two openings are respectively located at both ends of the hollow sponge bone needle.

[0019] A sponge spicule preparation or sponge spicule composition, wherein the sponge spicules contain more than 60% of the hollow sponge spicules described in claim 1.

[0020] Preferably, the hollow sponge bone needle is made by alkali soaking treatment of the original sponge bone needle. The property of silicon-based substances reacting with alkali to generate water-soluble silicates is utilized. An alkaline solution is added to the sponge bone needle, and the sponge bone needle is subjected to alkali soaking treatment to make it fully react with the alkaline solution. The tip of the sponge bone needle is dissolved by the alkaline solution and then opened to form an opening, thereby connecting the original internal closed channel with the outside, constructing a hollow channel of the sponge bone needle, and obtaining the hollow sponge bone needle.

[0021] Furthermore, the original sponge spicule includes at least one of a natural sponge spicule or an artificially prepared bionic sponge spicule; the morphology and properties of the artificially prepared bionic sponge spicule are similar to those of the natural sponge spicule.

[0022] Preferably, the raw sponge spicules include bee sponge spicules or artificially processed bee sponge spicules. Bee sponge spicules, derived from the bee sponge Haliclona sp., are slender rod-shaped with sharp ends. They are a newly discovered marine-derived natural microneedle with low production costs and flexible dosage and usage methods. They can effectively open the skin's stratum corneum, providing a channel for molecules to enter and exit the human body. The hollow sponge spicules prepared from bee sponge spicules are slender rod-shaped and have a hollow channel inside. The openings of this hollow channel are located at the two ends of the hollow sponge spicule.

[0023] Preferably, the length of the hollow sponge spicule is about 110-130 μm, the diameter is about 6-8 μm, and the average diameter of the channel is 1.0-1.4 μm.

[0024] There are nanoscale channels in the original sponge spicules, and both ends of the channels are closed (that is, the channels have no openings on the surface of the hollow sponge spicules), while the hollow sponge spicules of the present application form micrometer-scale hollow channels with openings at both ends.

[0025] The second technical solution adopted by the present invention to solve the technical problem is:

[0026] A method for preparing a hollow sponge spicule comprises reacting an original sponge spicule with an alkaline solution, dissolving the tip of the original sponge spicule by the alkaline solution, and then opening the tip to form an opening, thereby forming a hollow channel, and obtaining the hollow sponge spicule.

[0027] Specifically, the method includes placing the original sponge spicule into an alkaline solution and performing an oscillation treatment. After the oscillation treatment, the product is centrifuged to remove the supernatant, and then added into an acidic solution to neutralize to pH ≤ 8, washed, and dried to obtain the hollow sponge spicule.

[0028] Preferably, the formula ratio of the original sponge spicule to the alkaline solution is 0.08-0.12 g: 0.8-1.2 mL, and the concentration of the alkaline solution is 1-3 mol / L.

[0029] Preferably, the oscillation treatment time (ie, alkaline soaking time) is 45 to 50 hours. Furthermore, the size of the hollow channel inside the hollow sponge spicule can be adjusted by changing the oscillation treatment conditions.

[0030] The alkaline solution is sodium hydroxide solution; the acidic solution is ascorbic acid solution; the concentration of the acidic solution is 0.1-0.3%. The shaking treatment conditions are 200-250 rpm and room temperature; the centrifugal speed is 450-550 rpm and the centrifugal time is 1-3 minutes; the drying conditions are 45-55°C and 45-50 hours.

[0031] Furthermore, in a specific embodiment, the method for preparing hollow sponge spicules using bee sponge spicules includes:

[0032] 1) Place natural bee sponge spicules in a sodium hydroxide alkaline solution. For every 0.1g of natural bee sponge spicules, add 1mL of alkaline solution.

[0033] 2) Place the soaked bee sponge spicules in a shaker at 220 rpm and shake at room temperature for 48 hours;

[0034] 3) Remove the spicules after shaking and centrifuge at 500 rpm for 2 minutes. Remove the supernatant and add 10% ascorbic acid solution to neutralize the pH of the spicules. Then, shake and centrifuge to remove the supernatant. Repeat this process until the pH returns to below 8.

[0035] 4) Add 10 mL of deionized water to rinse the obtained bone spicule sample to remove the residual ascorbic acid solution, then shake and centrifuge to remove the supernatant, add 10 mL of ethanol, shake and centrifuge to remove the supernatant.

[0036] 5) The obtained sample was placed in an oven at 50°C for drying for 48 hours.

[0037] The third technical solution adopted by the present invention to solve the technical problem is:

[0038] Use of hollow sponge spicules in preparing a transdermal delivery system for a target substance in vitro.

[0039] Sponge spicules, as a biomaterial, are useful in delivering drugs and other target substances through the skin into the human body. Specifically, the delivery method involves using hollow sponge spicules to create microchannels in the skin. These microchannels include the gaps between the hollow sponge spicules and the skin, as well as the hollow channels within the hollow sponge spicules. These microchannels can serve as transport pathways for drugs and other target substances, thereby opening unobstructed hollow channels for drugs and other target substances administered externally to the skin. In vitro target substances can enter the body through the microchannels by free diffusion, achieving transdermal delivery. This improves the transdermal delivery efficiency of drugs and other target substances, especially macromolecular substances, significantly increasing the delivery dose and the molecular weight range of deliverable substances.

[0040] The fourth technical solution adopted by the present invention to solve the technical problem is:

[0041] A transdermal delivery system for an in vitro target substance comprises the hollow sponge bone needle.

[0042] The fifth technical solution adopted by the present invention to solve the technical problem is:

[0043] A method for percutaneously delivering an in vitro target substance using a hollow sponge spicule, wherein the hollow sponge spicule is applied to the skin, allowing the in vitro target substance to penetrate into the skin through microchannels opened by the hollow sponge spicule on the skin, thereby improving the delivery efficiency of the target substance and achieving directional transport; the microchannels include the gap formed between the hollow sponge spicule and the skin, as well as the hollow channel inside the hollow sponge spicule.

[0044] In a specific embodiment, the transdermal drug delivery technology embodiment is:

[0045] A method for transdermal drug delivery using hollow sponge bone needles, wherein the sponge bone needles are applied to the skin so that the bone needles can open microchannels on the skin, promoting the target substance to diffuse freely or allowing drug ions to penetrate into the skin through gaps around the bone needles and hollow channels in the middle of the bone needles in a manner of charged particle repulsion by externally applied voltage, thereby increasing the concentration or content of the target substance in the body (such as in the skin or blood) and improving the drug penetration efficiency to a greater extent.

[0046] More specifically, the sponge spicules are applied to the skin surface and massaged, with the applied spicule suspension having a concentration of 80 to 120 mg / mL. The target substance is then applied to the massaged skin.

[0047] Preferably, the dosage of the sponge spicule applied to the skin is 1-10 mg / cm 2 .

[0048] Furthermore, the massage method is electric massage or manual massage.

[0049] The sixth technical solution adopted by the present invention to solve the technical problem is:

[0050] Use of hollow sponge bone needles combined with a physical penetration enhancement device in preparing a transdermal delivery device for an in vitro target substance.

[0051] Preferably, the physical penetration-enhancing device is an iontophoresis instrument.

[0052] In a specific embodiment, the method of percutaneously delivering an in vitro target substance using a hollow sponge bone needle combined with a physical penetration-enhancing device includes: preparation of a hollow sponge bone needle solution: using a certain amount of deionized water (RO water) to prepare a hollow sponge bone needle solution with a concentration of 80 to 120 mg / mL; taking 80 to 120 microliters of the hollow sponge bone needle suspension, applying it to the cleaned skin, and electrically massaging for 1 to 3 minutes; taking 180 to 220 microliters of the target substance solution, placing it on the skin after the bone needles are applied, and using a physical penetration-enhancing device such as an ion introduction device to penetrate and introduce it for 14 to 18 hours.

[0053] Iontophoresis is designed to apply electricity to the skin based on the charge characteristics of the anode attracting anions and the cathode attracting cations, thereby directing the transfer of charged target substances into the skin. Based on the characteristics of the drug, an electrode with an opposite charge is introduced into the skin, while an electrode with the same charge is placed outside the skin. A short, microcurrent is applied to the skin surface, thereby enhancing drug delivery efficiency.

[0054] The seventh technical solution adopted by the present invention to solve the technical problem is:

[0055] A transdermal delivery device comprises a penetration enhancer and a physical penetration enhancing device, wherein the penetration enhancer comprises a hollow sponge bone needle and the physical penetration enhancing device comprises an ion introduction apparatus.

[0056] The term "in vivo" as used herein refers to the skin, blood, extracellular fluid, tissues, or organs. The skin comprises the stratum corneum, epidermis, and dermis. The sponge spicules described herein promote the absorption of substances by the skin primarily by utilizing the puncture effect of the sponge spicules, which opens the outer protective layer of the skin and allows the drug to penetrate through the hollow channel of the spicules and reach the deeper layers of the skin.

[0057] The target substance described in the present invention includes at least one of an endogenous target substance and an exogenous target substance. The endogenous target substance refers to substances contained in or produced by the human body, such as glucose, urea, lactic acid, and cysteine. The exogenous target substance refers to substances ingested by the human body from the outside, such as drugs or active ingredients. Active ingredients refer to substances that have certain physiological or pharmacological effects but have not been evaluated or have not yet been evaluated as drugs.

[0058] For example, the target substance includes charged ionic drugs such as sodium fluorescein or fluorescent dextran.

[0059] Unless otherwise specified, the equipment, reagents, processes, parameters, etc. involved in the present invention are conventional equipment, reagents, processes, parameters, etc. and are not given as examples.

[0060] All ranges recited herein include all points within the range.

[0061] The terms “approximately”, “about” or “around” used in the present invention refer to the range or value within ±20% of the range.

[0062] In the present invention, the "room temperature" refers to the normal ambient temperature, which can be 10-30°C.

[0063] Compared with the background technology, this technical solution has the following advantages:

[0064] The present invention utilizes hollow sponge spicules and other spicules to open skin microchannels after being applied to the skin, and the hollow channels inside the hollow sponge spicules can directly construct a transfer bridge between the inside of the skin and the outside of the skin. The target substance in vitro penetrates into the skin by free diffusion, and the target substance in vivo can also penetrate out of the skin by free diffusion. Therefore, it can not only be used for transdermal delivery and penetration promotion of target substances in vitro, but also is especially suitable for target substances of biological macromolecules with large molecular weight or poor stability. Furthermore, ion introduction measures can also be performed on the skin to further improve the transfer rate of ionic target substances. The present invention provides a non-invasive, non-invasive, effective, highly universal, unrestricted drug delivery site and area, easy to operate, and efficient way to transfer substances from vitro to vivo. This method has little harm, good compliance, and can be used for continuous drug delivery. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] FIG1 is a graph showing the comparison of the opening sizes of the spicules of the bee sponge treated with alkaline solutions of different concentrations for different times in Example 1 and the untreated spicules.

[0066] FIG2 is a graph showing the comparison of the opening rates of the bee sponge spicules treated with alkaline solutions of different concentrations for different times in Example 1 and the untreated spicules.

[0067] Figure 3 compares the intactness of untreated honeybee sponge spicules treated with different concentrations of alkaline solution for different durations of time and ultrasonically treated with different concentrations of alkaline solution in Example 1. * indicates p < 0.05, ** indicates p < 0.01. Experimental data are presented as mean ± SD, n = 3.

[0068] Figure 4 is an electron microscope comparison of natural bee sponge spicules and bee sponge spicules treated with alkaline solution. The left picture is a natural bee sponge spicule, and the right picture is a hollow bee sponge spicule obtained after treatment with alkaline solution. It can be clearly seen that the tip of the hollow bee sponge spicule is dissolved, and the internal channel is opened to form a hollow channel.

[0069] Figure 5 is a confocal microscope image of the hollow bee sponge spicule obtained after alkaline solution treatment, which was taken using Nile red dye for staining. It can be seen that the Nile red dye has entered the interior of the spicule, proving that the spicule has formed a through-open channel, becoming a hollow spicule.

[0070] Figure 6 shows the comparative results of the fluorescein sodium hollow spicule group (hSHS), spicule group (SHS), iontophoresis group (ITP), hollow spicule and iontophoresis group (hSHS+ITP), spicule and iontophoresis group (SHS+ITP), control group, and blank group in Example 2. * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001. Experimental data are expressed as mean ± SD, n = 3.

[0071] Figure 7 shows confocal laser scanning microscopy images of pig skin sections after an in vitro transdermal delivery experiment of sodium fluorescein. (A) Control group, (B) Iontophoresis group (ITP), (C) Spine spicule group (SHS), (D) Hollow spicule group (hSHS), (E) Spine and iontophoresis group (SHS+ITP), and (F) Hollow spicule and iontophoresis group (hSHS+ITP).

[0072] FIG8 shows the permeability of sodium fluorescein into various skin layers after in vitro transdermal delivery (SHS: honeybee sponge spicules; hSHS: honeybee sponge hollow spicules; ITP: iontophoresis).

[0073] Figure 9 shows the comparative results of the fluorescent dextran hollow spicule group (hSHS group), spicule group (SHS group), iontophoresis group (ITP), hollow spicule and iontophoresis group (hSHS+ITP), spicule and iontophoresis group (SHS+ITP), control group, and blank group in Example 3. ** indicates p < 0.01. Experimental data are expressed as mean ± SD. n = 3. DETAILED DESCRIPTION

[0074] The following examples further illustrate and describe the technical solutions involved in the present invention. Obviously, it should be understood that the present invention is not limited to the contents listed below, and the terms and embodiments used are not intended to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0075] Example 1

[0076] The bee sponge spicules are treated by soaking them in an alkaline solution to open the hollow channels.

[0077] 0.1 g of untreated bone spicules were placed in an EP tube, 1 mL of NaOH solution was added, and the tube was placed in a shaker at 220 rpm for shaking and mixing.

[0078] The concentrations of NaOH solution are 0.5 mol / L, 1 mol / L, and 2 mol / L; the shaking times are 45 min, 90 min, 24 h, 48 h, and 72 h, respectively. Therefore, there are 16 groups in total, namely, alkali solution concentration of 0.5mol / L, alkali soaking time of 45min; alkali solution concentration of 0.5mol / L, alkali soaking time of 90min; alkali solution concentration of 0.5mol / L, alkali soaking time of 24h; alkali solution concentration of 0.5mol / L, alkali soaking time of 48h; alkali solution concentration of 0.5mol / L, alkali soaking time of 72h; alkali solution concentration of 1mol / L, alkali soaking time of 45min; alkali solution concentration of 1mol / L, alkali soaking time of 90min; alkali solution concentration of 1mol / L, alkali soaking time of 24h; alkali solution concentration of 1mol / L, alkali soaking time of 48h; alkali solution concentration of 1mol / L, alkali soaking time of 72h; alkali solution concentration of 2mol / L, alkali soaking time of 45min; alkali solution concentration of 2mol / L, alkali soaking time of 90min; alkali solution concentration of 2mol / L, alkali soaking time of 24h; alkali solution concentration of 2mol / L, alkali soaking time of 48h; alkali solution concentration of 2mol / L, alkali soaking time of 72h. There were 15 experimental groups in total, and untreated spicules served as a control group.

[0079] The alkali-treated bone spicule solution was centrifuged at 500 rpm for 2 minutes. The supernatant was removed, and 10% ascorbic acid solution was added to neutralize the alkali solution. The supernatant was removed by centrifugation. This process was repeated until the pH of the solution was below 8. Deionized water was added to rinse the remaining ascorbic acid solution. The supernatant was removed by centrifugation, and ethanol was added to rinse the remaining liquid. The supernatant was removed by centrifugation, and the resulting bone spicules were placed in an oven at 50°C for 48 hours to ensure they were dry.

[0080] Characterization of hollow bone spicule preparation results:

[0081] Sampling method: Use deionized water (RO water) to make a suspension of the alkali-soaked bone needles, then use a pipette to take 1 to 2 drops of sample, add it to the slide, and press it with a cover glass for subsequent microscopic observation.

[0082] Opening Size: At least 15 intact spicules were observed under an automated upright microscope using a 100× objective and a 10× eyepiece. The length of the opening (in μm) was measured using Image J software, and the mean and SD values ​​were calculated. The statistical results are shown in Figure 1. Clearly, the opening size of the spicule channels in the treatment conditions of 2 mol / L alkali solution for 48 hours and 2 mol / L alkali solution for 72 hours was significantly larger than in the other treatment groups, and the results of the data analysis were statistically significant.

[0083] Opening Rate: Ten random fields of view were observed under an optical microscope using a 40× objective lens and a 10× eyepiece. The number of intact and open spicules within the field of view was counted. The opening rate of the spicules was calculated. The statistical processing results are shown in Figure 2. It is clearly seen that the opening rates of the 2 mol / L alkali solution with a soak time of 48 hours and the 2 mol / L alkali solution with a soak time of 72 hours were significantly higher than those of the other groups, and the results of the data analysis were statistically significant.

[0084] Ultrasonication Integrity Rate: Ten random fields of view were observed under an optical microscope using a 20× objective lens and a 10× eyepiece before and after ultrasonication. Images were taken and the area occupied by spicules within the images was measured using Image J to ensure uniform spicule density within each image. Ultrasonic cell disruptors were then used at 65% ultrasonic intensity for 7 minutes, with an on-time of 1 second and a rest time of 1 second. The number of intact spicules within the images was counted, and the post-ultrasonication spicule integrity rate was calculated. The statistical results are shown in Figure 3. It is clearly evident that at 72 hours of alkali soaking, the spicule integrity rate decreased significantly compared to untreated spicules and spicules from the other treatment conditions. The statistical analysis results were significant, indicating that the hardness of the spicules is significantly affected by the alkali soaking treatment. Prolonged alkali soaking times are not conducive to subsequent transdermal drug delivery experiments. Therefore, alkali soaking times should be kept to a minimum.

[0085] Through the above-mentioned characterization experiment of the hollow spicules of bee sponges after alkali soaking treatment, it can be judged that the optimal conditions for preparing hollow spicules are an alkali solution concentration of 2 mol / L and an alkali soaking time of 48 h.

[0086] Example 2

[0087] Preliminary processing of pig skin: Take fresh pig skin, remove the subcutaneous fat layer, shave the pig hair to a length of no longer than 2mm, use immediately or freeze at -20℃~-80℃ for later use.

[0088] In vitro permeation test: Pig skin samples of the same diameter were drilled using a circular punch and mounted on a Franz diffusion transdermal apparatus. Transcutaneous resistance testing was performed to measure changes in skin conductance before and after application of the sponge spicule solution. If the conductance of the ex vivo pig skin was no higher than 10 μA before application, this indicated that the stratum corneum barrier function was intact and suitable for subsequent experiments.

[0089] Preparation of bee sponge spicule solution: Take a certain amount of bee sponge spicule (SHS) and add physiological saline to make the spicule concentration reach 100 mg / mL.

[0090] Preparation of hollow bee sponge spicule solution: Take a certain amount of hollow bee sponge spicule (hSHS) and add physiological saline to make the spicule concentration reach 100 mg / mL.

[0091] Electric massage: Use an electric massage stick, with a force of 0.3N, to ensure that the massage stick is lightly against the skin, turn on the massage stick switch, and perform electric massage for 2 minutes.

[0092] Delivery of sodium fluorescein: divided into hollow bone needle and iontophoresis co-delivery group, ordinary bone needle and iontophoresis co-delivery group, hollow bone needle delivery group, ordinary bone needle delivery group, iontophoresis treatment delivery group, control group and blank group.

[0093] Hollow spicule delivery group: 100 μL of hollow bee sponge spicule solution was directly applied to excised porcine skin (total hollow spicules, 10 mg) and massaged with electric massage for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining using RO water rinsing and wiped clean with a disposable paper towel. 500 μL of sodium fluorescein solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the sodium fluorescein solution to contact the skin after the spicule application and massage. The sodium fluorescein solution was allowed to remain on the skin surface and then be delivered into the skin. Transdermal delivery was performed at 37°C, 600 rpm for 16 hours.

[0094] In the conventional spicule delivery group, 100 μL of the honeybee sponge spicule solution was applied directly to the excised pig skin (total spicule volume 10 mg) and massaged with electric force for 2 minutes. Afterwards, the skin surface was cleaned of any residual spicule suspension using RO water and wiped clean with a disposable tissue. 500 μL of sodium fluorescein solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the sodium fluorescein solution to contact the skin after the spicule application and massage. The sodium fluorescein solution remained on the skin surface and was then delivered into the skin. Transdermal delivery was performed at 37°C and 600 rpm for 16 hours.

[0095] Hollow spicule and iontophoresis synergistic delivery group: 100 μL of hollow bee sponge spicule solution was directly applied to excised porcine skin (total hollow spicules, 10 mg) and electrically massaged for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining with RO water and wiped clean with a disposable paper towel. 500 μL of sodium fluorescein solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the sodium fluorescein solution to contact the skin after the spicule application and massage. The sodium fluorescein solution remained on the skin surface and was then delivered into the skin. Then, using an Ag-AgCl electrode, the cathode was fixed in the dosing chamber in contact with the sodium fluorescein solution, and the anode was placed in the sampling arm in contact with a 0.2 mol / L PBS solution. A current of 0.5 mA was applied for 15 minutes, and transdermal delivery was carried out at 37°C and 600 rpm for 16 hours.

[0096] Conventional spicule and iontophoresis co-delivery group: 100 μL of honeybee sponge spicule solution was applied directly to excised porcine skin (total spicules, 10 mg) and massaged electrically for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining with RO water and wiped clean with a disposable paper towel. 500 μL of sodium fluorescein solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the sodium fluorescein solution to contact the skin after the spicule application and massage. The sodium fluorescein solution remained on the skin surface and was then delivered into the skin. Then, using an Ag-AgCl electrode, the cathode was fixed in the dosing chamber, in contact with the sodium fluorescein solution, and the anode was placed in the sampling arm, in contact with a 0.2 mol / L PBS solution. A current of 0.5 mA was applied for 15 minutes, and transdermal delivery was carried out at 37°C and 600 rpm for 16 hours.

[0097] Iontophoresis treatment delivery group: 500 μL of sodium fluorescein solution was added to the dosing chamber above the Franz diffusion transdermal device so that the sodium fluorescein solution could contact the skin and stay on the skin surface. Then, an Ag-AgCl electrode was used, with the cathode fixed in the dosing cell in contact with the sodium fluorescein solution, and the anode placed in the sampling arm in contact with 0.2 mol / L PBS solution. A current of 0.5 mA was applied, and the treatment was carried out for 15 min. The transdermal treatment was carried out at 37°C and 600 r / min for 16 h.

[0098] The control group did not receive sponge bone needle massage or iontophoresis treatment. Instead, 500 μL of sodium fluorescein was placed directly on the skin directly below the dosing pool and percutaneously at 37°C and 600 rpm for 16 h.

[0099] The blank group did not receive sponge bone needle massage or iontophoresis treatment. Instead, 500 μL of PBS solution was directly placed on the skin directly below the dosing reservoir and percutaneously incubated at 37°C and 600 rpm for 16 h.

[0100] Skin samples after transdermal experiments were collected from the hollow bone needle and iontophoresis co-delivery group, ordinary bone needle and iontophoresis co-delivery group, hollow bone needle delivery group, ordinary bone needle delivery group, iontophoresis treatment delivery group, control group and blank group. After being taken out from the transdermal pool, the surface and back of the skin were cleaned with RO water and anhydrous ethanol to remove the residual drug solution.

[0101] Determination of sodium fluorescein content in the skin: Using the tape stripping extraction method, the 1st to 10th layers of the stratum corneum were sequentially stripped with tape, the viable epidermis was isolated, and the dermis was partially minced. Each layer was immersed in 4 mL of a 0.05 mol / L PBS / methanol (1:1) solution and extracted at room temperature at 180 rpm for 24 hours. The resulting sample was diluted with a 0.05 mol / L PBS / methanol (1:1) solution and the sodium fluorescein content was measured using a microplate reader at the sodium fluorescein detection wavelengths (excitation wavelength: 485 nm and emission wavelength: 535 nm). The data were calculated to determine the sodium fluorescein content in the stratum corneum, epidermis, and dermis, respectively.

[0102] The solution in the receiving cell of each group of samples was collected and diluted with 0.2 mol / L PBS solution. The sodium fluorescein content was then detected using an enzyme-labeled instrument according to the detection wavelength of sodium fluorescein (excitation wavelength: 485 nm and emission wavelength: 535 nm), and the sodium fluorescein content in the receiving cell was calculated.

[0103] The results showed that compared with the ordinary bone needle and iontophoresis synergistic delivery group (SHS+ITP), the ordinary bone needle delivery group (SHS), the iontophoresis treatment delivery group (ITP), the control group and the blank group, the hollow bone needle delivery group (hSHS) and the hollow bone needle and iontophoresis combined drug delivery group (hSHS+ITP) can effectively enhance the skin absorption of sodium fluorescein, see Figure 6.

[0104] Confocal microscopy observation of pig skin samples for in vitro transdermal transdermal testing: Two samples were taken from the dosing area of ​​the pig skin using a 5 mm diameter sampler. The samples were frozen and sealed with OCT cryogel and stored at -80°C overnight. The samples were then sliced ​​to 10 μm thickness using a microtome, mounted with neutral resin, and stored in the dark for 12 hours. The samples were observed under a confocal microscope, and the fluorescence of the pig skin slices was photographed. See Figure 7.

[0105] The absorption rate of sodium fluorescein in different skin layers is shown in Figure 8. As the treatment conditions are superimposed, the deeper the skin layer, the higher the sodium fluorescein content. Compared with other treatment groups, the sodium fluorescein content in the hollow bone needle and iontophoresis co-delivery group (hSHS+ITP) has a significant increase, and the increase in content in the receiving pool is most obvious.

[0106] Example 3

[0107] Preliminary processing of pig skin: Take fresh pig skin, remove the subcutaneous fat layer, shave the pig hair to a length of no longer than 2mm, use immediately or freeze at -20℃~-80℃ for later use.

[0108] In vitro permeation test: Pig skin samples of the same diameter were drilled using a circular punch and mounted on a Franz diffusion transdermal apparatus. Transcutaneous resistance testing was performed to measure changes in skin conductance before and after application of the sponge spicule solution. If the conductance of the ex vivo pig skin was no higher than 10 μA before application, this indicated that the stratum corneum barrier function was intact and suitable for subsequent experiments.

[0109] Preparation of bee sponge spicule solution: Take a certain amount of bee sponge spicule (SHS) and add physiological saline to make the spicule concentration reach 100 mg / mL.

[0110] Preparation of hollow bee sponge spicule solution: Take a certain amount of hollow bee sponge spicule (hSHS) and add physiological saline to make the spicule concentration reach 100 mg / mL.

[0111] Electric massage: Use an electric massage stick, with a force of 0.3N, ensure that the massage stick rests lightly on the skin, turn on the massage stick switch, and perform electric massage for 2 minutes.

[0112] Delivery of fluorescent dextran (20KDa): divided into hollow bone needle and iontophoresis co-delivery group, ordinary bone needle and iontophoresis co-delivery group, hollow bone needle delivery group, ordinary bone needle delivery group, iontophoresis treatment delivery group, control group and blank group.

[0113] Hollow spicule and iontophoresis synergistic delivery group: 100 μL of hollow bee sponge spicule solution was directly applied to excised porcine skin (total hollow spicules, 10 mg) and electrically massaged for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining with RO water rinsing and wiped clean with a disposable paper towel. 200 μL of fluorescent dextran solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the fluorescent dextran solution to contact the skin after the spicule application and massage. The fluorescent dextran solution remained on the skin surface and was then delivered into the skin. Then, using an Ag-AgCl electrode, the anode was fixed in the dosing chamber in contact with the sodium fluorescein solution, and the cathode was placed in the sampling arm in contact with a 0.1 mol / L citric acid-sodium citrate buffer solution. A current of 0.5 mA was applied for 15 minutes, and transdermal delivery was carried out at 37°C and 600 rpm for 16 hours.

[0114] Conventional spicule and iontophoresis co-delivery group: 100 μL of honeybee sponge spicule solution was directly applied to excised porcine skin (total spicule volume 10 mg) and electrically massaged for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining with RO water rinsing and wiped clean with a disposable paper towel. 200 μL of fluorescent dextran solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the sodium fluorescein solution to contact the skin after the spicule application and massage. The fluorescent dextran solution remained on the skin surface and was then delivered into the skin. Then, using an Ag-AgCl electrode, the anode was fixed in the dosing chamber in contact with the fluorescent dextran solution, and the cathode was placed in the sampling arm in contact with a 0.1 mol / L citric acid-sodium citrate buffer solution. A current of 0.5 mA was applied for 15 minutes, and transdermal delivery was carried out at 37°C and 600 rpm for 16 hours.

[0115] Hollow spicule delivery group: 100 μL of hollow bee sponge spicule solution was directly applied to excised porcine skin (total 10 mg of hollow spicules) and massaged with electric massage for 2 minutes. Afterwards, the skin surface was cleaned of any spicule suspension remaining using RO water rinsing and wiped clean with a disposable paper towel. 200 μL of fluorescent dextran solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the fluorescent dextran solution to contact the skin after the spicule application and massage. The fluorescent dextran solution was allowed to remain on the skin surface and then be delivered into the skin. Transdermal delivery was performed at 37°C, 600 rpm for 16 hours.

[0116] In the conventional spicule delivery group, 100 μL of the honeybee sponge spicule solution was applied directly to excised porcine skin (total spicules: 10 mg). The skin was then massaged with electric massage for 2 minutes. Afterwards, any residual spicule suspension on the skin surface was cleaned with RO water and wiped clean with a disposable tissue. A 200 μL fluorescent dextran solution was added to the upper dosing chamber of the Franz diffusion transdermal device, allowing the fluorescent dextran solution to contact the skin after the spicule application and massage. The fluorescent dextran solution remained on the skin surface and was then delivered into the skin. The transdermal flow was maintained at 37°C and 600 rpm for 16 hours.

[0117] Iontophoresis treatment delivery group: 200 μL of fluorescent dextran solution was added to the dosing chamber above the Franz diffusion transdermal device so that the fluorescent dextran solution could contact the skin and stay on the skin surface. Then, an Ag-AgCl electrode was used, and the anode was fixed in the dosing cell in contact with the fluorescent dextran solution. The cathode was placed in the sampling arm in contact with 0.1 mol / L citric acid-sodium citrate buffer solution, and a current of 0.5 mA was applied. The treatment was energized for 15 min, and the transdermal treatment was carried out at 37°C and 600 r / min for 16 h.

[0118] The control group did not receive sponge bone needle massage or iontophoresis treatment. Instead, 200 μL of fluorescent dextran was placed directly on the skin directly below the dosing pool and permeated at 37°C and 600 rpm for 16 h.

[0119] The blank group did not receive sponge bone needle massage or iontophoresis treatment. Instead, 200 μL of PBS solution was directly placed on the skin directly below the dosing reservoir and permeated at 37°C and 600 rpm for 16 h.

[0120] Skin samples after transdermal experiments were collected from the hollow bone needle and iontophoresis co-delivery group, ordinary bone needle and iontophoresis co-delivery group, hollow bone needle delivery group, ordinary bone needle delivery group, iontophoresis treatment delivery group, control group and blank group. After being taken out from the transdermal pool, the surface and back of the skin were cleaned with RO water and anhydrous ethanol to remove the residual drug solution.

[0121] Determination of fluorescent dextran content in skin layers: Using the tape stripping extraction method, the 1st to 10th layers of the stratum corneum were sequentially stripped with tape, the viable epidermis was isolated, and the dermis was partially minced. Each layer was immersed in 4 mL of a 0.05 mol / L PBS / methanol (1:1) solution and extracted at room temperature at 180 rpm for 24 hours. The resulting sample was diluted with a 0.05 mol / L PBS / methanol (1:1) solution, and the fluorescent dextran content was measured using a microplate reader at the fluorescent dextran detection wavelength (excitation wavelength: 490 nm and emission wavelength: 530 nm). The data were calculated to determine the fluorescent dextran content in the stratum corneum, epidermis, and dermis, respectively.

[0122] The solution in the receiving pool of each group of samples was collected separately, diluted with 0.2 mol / L PBS solution, and then the fluorescent dextran content was detected using an enzyme marker according to the detection wavelength of fluorescent dextran (excitation wavelength: 490 nm and emission wavelength: 530 nm), and the fluorescent dextran content in the receiving pool was calculated.

[0123] The results showed that compared with other groups, the hollow bone needle and iontophoresis intervention drug delivery group (hSHS+ITP) can effectively enhance the skin's absorption of fluorescent dextran, see Figure 9.

[0124] The above description is merely a preferred embodiment of the present invention and therefore cannot be used to limit the scope of the present invention. In other words, equivalent changes and modifications made according to the scope of the present invention and the contents of the specification should still fall within the scope of the present invention. Industrial Applicability

[0125] The present invention discloses hollow sponge spicules, their preparation method, and applications. Specifically, a method for preparing hollow sponge spicules using bee sponge spicules as a basic raw material is disclosed, as well as characterization data after the preparation method. The preparation method uses an alkaline solution prepared with sodium hydroxide as a treatment agent to soak and vibrate the sponge spicules, thereby achieving the purpose of reacting the alkaline solution with the silicon substances contained in the spicules, so that the spicules produce hollow channels. This in turn improves the efficiency of transdermal drug delivery and increases drug utilization, thereby significantly promoting more efficient, stable, and safe transdermal absorption of a series of biomacromolecules such as drugs and cosmetic active ingredients, and has industrial applicability.

Claims

1. A hollow sponge spicule, characterized in that: The hollow sponge spicule has at least one hollow channel inside; the channel has at least two openings on the surface of the hollow sponge spicule.

2. The hollow sponge spicule according to claim 1, characterized in that: The hollow sponge spicule is made from original sponge spicules, and the original sponge spicules include at least one of natural sponge spicules or artificially prepared bionic sponge spicules; preferably, the original sponge spicules include bee sponge spicules.

3. The hollow sponge spicule according to claim 1, characterized in that: The average diameter of the channel is 1.0-1.4 μm.

4. A sponge spicule preparation or a sponge spicule composition, wherein the hollow sponge spicules according to claim 1 account for more than 60% of the sponge spicules.

5. A method for preparing the hollow sponge spicule according to any one of claims 1 to 3, characterized in that: The original sponge spicule is reacted with an alkaline solution to open the tip of the original sponge spicule to form an opening, thereby forming the hollow channel and obtaining the hollow sponge spicule.

6. The preparation method according to claim 5, characterized in that: The original sponge bone needle is placed in an alkaline solution and subjected to an oscillation treatment. After the oscillation treatment product is centrifuged to remove the supernatant, an acidic solution is added to neutralize it to a pH value of ≤8, and the product is washed and dried to obtain the hollow sponge bone needle. Preferably, the formula ratio of the original sponge bone needle to the alkaline solution is 0.08-0.12g: 0.8-1.2mL, and the concentration of the alkaline solution is 1-3mol / L; the oscillation treatment time is 45-50h.

7. Use of hollow sponge bone needles in preparing a transdermal delivery system for a target substance in vitro.

8. A transdermal delivery system for an in vitro target substance, characterized in that: The percutaneous delivery system includes the hollow sponge spicule.

9. Use of hollow sponge bone needles combined with physical penetration enhancement equipment in the preparation of a transdermal delivery device for in vitro target substances.

10. The use according to claim 8, characterized in that: The physical penetration-promoting device is an ion introduction instrument.

11. A transdermal delivery device, characterized in that: The invention comprises an osmotic enhancer and a physical osmotic enhancer device. The osmotic enhancer comprises a hollow sponge bone needle, and the physical osmotic enhancer device comprises an ion introduction instrument.

Citation Information

Patent Citations

  • Method for purifying and extracting spicules from natural bio-sponge obtained from sponge

    CN106413723A

  • Painless drug administration patch for skin

    CN108704218A

  • Preparation method of high-purity sponge bone needle and application as skin penetration enhancerthereof

    CN109820812A

  • Surface-modified sponge spicule, preparation method and applications thereof

    CN111012916A

  • Mesoporous sponge spicule as well as preparation method and application of mesoporous sponge spicule

    CN112237567A